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AUTHORIZES BONDS CONTINUING 
STEM CELL RESEARCH.
INITIATIVE STATUTE. 
OFFICIAL TITLE AND SUMMARY P R E P A R E D  B Y  T H E  A T T O R N E Y  G E N E R A L  
The text of this measure can be found on page 89 and the Secretary of State’s website at 
voterguide.sos.ca.gov. 
• Authorizes $5.5 billion in state general 
obligation bonds to fund grants from 
the California Institute of Regenerative 
Medicine to educational, nonprofit, and 
private entities for: stem cell and other 
medical research, including training; stem 
cell therapy development and delivery; 
research facility construction; and 
associated administrative expenses. 
• Dedicates $1.5 billion to research and 
therapy for Alzheimer’s, Parkinson’s, 
stroke, epilepsy, and other brain and 
central nervous system diseases and 
conditions. 
• Appropriates General Fund moneys to pay 
bond debt service. 
• Expands programs promoting stem cell 
and other medical research, therapy 
development and delivery, and student and 
physician training and fellowships. 
SUMMARY OF LEGISLATIVE ANALYST’S ESTIMATE 
OF NET STATE AND LOCAL GOVERNMENT 
FISCAL IMPACT: 
• Increased state costs to repay bonds 
estimated at about $260 million per year 
over the next roughly 30 years. 
Summary of State Costs 
New Borrowing 
Principal $5.5 billion 
Interest 2.3 billion 
Total Estimated Cost $7.8 billion 
Payments 
Average annual cost $260 million 
Assumed payment period 30 years 
Source of payments Primarily General Fund 
tax revenue 
ANALYSIS BY THE LEGISLATIVE ANALYST 
BACKGROUND 
Researchers Use Stem Cells to Study and 
Treat Many Diseases. Stem cells are certain 
types of cells that exist within humans. 
Researchers are interested in stem cells for 
their potential to regenerate cells, tissues, 
and organs, thereby potentially helping to 
treat or cure certain diseases. Researchers 
engaged in “regenerative medicine” are 
focused on addressing many diseases, 
including Alzheimer’s disease, HIV/AIDS, 
stroke, diabetes, and cancer. 
Voters Approved Earlier Stem Cell Ballot 
Measure. In 2004, voters approved 
Proposition 71, which added a provision to 
the State Constitution affirming the right of 
researchers in California to conduct stem 
cell research. The measure also created 
the California Institute for Regenerative 
Medicine (CIRM), primarily for the purpose 
of providing grants to universities and other 
entities in California to support stem cell 
research, development of new treatments, 
clinical trials, new research facilities, 
and other related activities. The measure 
also established (1) a governing board to 
adopt CIRM policies and allocate grant 
funds, (2) three advisory working groups to 
help guide the governing board on certain 
matters, and (3) an independent oversight 
committee to review CIRM’s finances. 
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Measure Allowed State to Issue General 
Obligation Bonds. Proposition 71 allowed the 
state to sell $3 billion in general obligation 
bonds, which are a form of borrowing. The 
state sold the bonds to investors, and the 
money generated from these sales funded 
CIRM grants and operations. After selling 
bonds, the state has been repaying investors 
with interest over many years. As is typically 
the case with these kinds of bonds, the state 
has made most debt payments from the 
General Fund—the state’s main operating 
account, which pays for education, prisons, 
health care, and other public services. The 
measure required that a small amount of 
interest be paid by funds from the bond 
sales. (For more information on the state’s 
use of bonds, see “Overview of State Bond 
Debt” later in this guide.) 
C O N T I N U E D  
Grants Have Funded Several Purposes. 
Figure 1 shows how CIRM has used its grant 
funding. Funded projects have involved 
conducting basic science research (such 
as laboratory research on stem cells), 
developing potential treatments, and 
undertaking clinical trials. Grant funds also 
have supported other activities, including 
construction of new research facilities and 
research internships for college students. 
The University of California has received 
the greatest amount of grant funding, 
followed by private nonprofit universities and 
institutions (such as Stanford University). 
In addition to receiving a grant from CIRM, 
many grant recipients receive additional 
funding from other sources for their projects. 
Other common fund sources are industry 
$2.7 Billion Awarded Since 2004 
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contributions, private donations, and federal 
grants. 
Grant Recipients Are Required to Share 
Invention-Related Income With the State. 
Some stem cell research can lead to 
new inventions, including new medical 
technologies and treatments. Proposition 71 
required grant recipients who license or sell 
their inventions to share a portion of the 
resulting income with the state. The state’s 
share of the income is deposited into the 
General Fund and may be used to support 
any state program. Over the years, CIRM’s
governing board has developed rules for how 
income revenue is shared with the state. 
The state began receiving income from 
CIRM-funded inventions in 2017. To date, 
these inventions have provided a total of 
approximately $350,000 to the state. 
CIRM Has Spent Nearly All Available Funds. As 
of June 2020, CIRM had spent most of its 
Proposition 71 funds. According to CIRM, 
around $30 million remains available for 
grants. As it nears the end of its funding, 
CIRM has been decreasing its staffing. The 
institute currently employs 35 full-time 
staff, down from its peak of over 50 full-time 
staff. It plans to maintain some staff for the 
next few years as remaining projects are 
completed. 
PROPOSAL 
Authorizes New Bonds for Stem Cell Activities. 
Proposition 14 allows the state to sell 
$5.5 billion in general obligation bonds. The 
bonds primarily would fund additional grants 
to support research and the development 
of treatments (including clinical trials) for 
many diseases. The proposition sets aside at 
least $1.5 billion specifically to research and 
develop treatments for diseases affecting 
the brain and central nervous system (such 
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as Alzheimer’s disease and Parkinson’s 
disease). The proposition directs CIRM to 
allocate a small share of grant funding for 
training opportunities for students at the 
California State University and the California 
Community Colleges, as well as a small 
share for helping to establish and support 
facilities focused on research and clinical 
trials. For some types of grants, CIRM 
would be required to ensure grant recipients 
are located across the state and prioritize 
applicants that offer matching funds. The 
proposition allows CIRM to spend no more 
than 7.5 percent of bond funds on its 
administrative costs. 
Establishes Certain Rules Relating to the Bonds. 
The proposition limits the amount of bonds 
the state could sell to $540 million per year, 
thereby spreading out bond sales over at 
least 11 years. For the first five years after 
the proposition is approved, the state would 
make interest payments using funds from the 
bond sales, thereby reducing the amount of 
bond funding available for research projects. 
Beginning January 1, 2026, the state would 
no longer use funds from bond sales to make 
interest payments. Instead, the state would 
make remaining debt payments from the 
General Fund. 
Makes Numerous Changes to CIRM. Most 
notably, the proposition makes several 
changes intended to improve patient access 
to stem cell treatments. The proposition 
allows CIRM to hire up to 15 full-time 
employees specifically for developing policies 
and programs relating to improving access to 
and affordability of treatments for patients. 
(The institute would be allowed up to 
70 full-time employees for other operational 
purposes.) A new advisory working group 
of experts would support CIRM’s governing 
board in these matters. Further, any 
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invention-related revenue that is deposited 
into the General Fund would be used to 
help pay for patients’ regenerative medicine 
treatments. Among various other changes, 
the proposition also increases the number of 
members on CIRM’s governing board from 
29 to 35. 
FISCAL EFFECTS 
Total Estimated State Costs of $7.8 Billion. The 
cost to repay the bonds authorized by this 
proposition depends on various factors, such 
as the interest rates on the bonds and the 
time period over which they are repaid. We
estimate the total cost to pay off the bonds 
would be $7.8 billion—$5.5 billion for the 
principal and $2.3 billion for the interest. 
State costs would average about $260 million 
per year for about 30 years. This amount is 
less than 1 percent of the state’s current 
General Fund budget. 
Difficult to Estimate Invention-Related Income 
Available for Patients’ Treatment Costs. The 
amount of revenue from new inventions that 
would be available to the state for helping 
to cover costs for patients’ regenerative 
medicine treatments is uncertain. Many 
times, research does not lead to an 
invention. Also, a significant amount of time 
C O N T I N U E D  
typically passes from starting a research 
project to licensing or selling an associated 
invention. To date, the state has collected a 
few hundred thousand dollars in invention-
related income. Past revenue collections, 
however, might not accurately predict future 
revenue. 
Other Possible Fiscal Effects. The proposition 
could result in numerous indirect effects on 
state and local governments. For example, 
if the proposition were to result in new 
treatments, state and local government costs 
for some programs such as Medi-Cal, the 
state’s subsidized health care program for 
low-income people, could be affected. The 
net fiscal impact of the indirect effects of 
this proposition is unknown. 
Visit http://cal-access.sos.ca.gov/campaign/ 
measures/ for a list of committees primarily 
formed to support or oppose this measure. 
Visit http://www.fppc.ca.gov/ 
transparency/top-contributors.html 
to access the committee’s top 10 contributors. 
A copy of the full text of this state measure 
can be found on page 89 of this guide. 
For the full text of Proposition 14, see page 89. Analysis | 19 
